FASEB J. Mp Biomedicals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shukla, S.
Right arrow Articles by Gupta, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shukla, S.
Right arrow Articles by Gupta, S.
The FASEB Journal Express Article doi:10.1096/fj.05-3740fje
Published online October 17, 2005

Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice

Sanjeev Shukla, Anil Mishra, Pingfu Fu, Gregory T. MacLennan, Martin I. Resnick, and Sanjay Gupta

E-mail contact: sanjay.gupta{at}case.edu

Epidemiological studies suggest that increased intake of fruits and vegetables may be associated with a reduced risk of prostate cancer. Apigenin (4', 5, 7,-trihydroxyflavone), a common dietary flavonoid abundantly present in fruits and vegetables, has shown remarkable anti-proliferative effects against various malignant cell lines. However, the mechanisms underlying these effects remain to be elucidated. We investigated the in vivo growth inhibitory effects of apigenin on androgen-sensitive human prostate carcinoma 22Rv1 tumor xenograft subcutaneously implanted in athymic male nude mice. Apigenin was administered to mice by gavage at doses of 20 and 50 μg/mouse/day in 0.2 ml of a vehicle containing 0.5% methyl cellulose and 0.025% Tween 20 in two different protocols. In the first protocol, apigenin was administered for 2 wk before inoculation of tumor and was continued for 8 wk, resulting in significant inhibition of tumor volume by 44 and 59% (P<0.002 and 0.0001), and wet weight of tumor by 41 and 53% (P<0.05), respectively. In the second protocol, administration of apigenin began 2 wk after tumor inoculation and continued for 8 wk; tumor volume and wet weights of tumor were reduced by 39 and 53% (P<0.01 and 0.002) and 31 and 42% (P<0.05), respectively. The tumor inhibitory effect of apigenin was more pronounced in the first protocol of extended treatment, which was associated with increased accumulation of human IGFBP-3 in mouse serum along with significant increase in IGFBP-3 mRNA and protein expression in tumor xenograft. Apigenin intake by these mice also resulted in simultaneous decrease in serum IGF-I levels and induction of apoptosis in tumor xenograft. Importantly, tumor growth inhibition, induction of apoptosis, and accumulation of IGFBP-3 correlated with increasing serum and tumor apigenin levels. In both studies, animals did not exhibit any signs of toxicity or reduced food consumption. In cell culture studies, apigenin treatment resulted in cell growth inhibition and induction of apoptosis, which correlated with increased accumulation of IGFBP-3 in culture medium and cell lysate. These effects were associated with significant reduction in IGF-I secretion; inhibition of IGF-I-induced cell cycle progression and insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation, along with an increase in sub-G1 peak by apigenin. Further, treatment of cells with IGFBP-3 antisense oligonucleotide reversed these effects and attenuated apigenin-mediated inhibition of IRS-1 phosphorylation conferring inhibitory effects of apigenin on IGF-signaling. This study presents the first evidence that the in vitro and in vivo growth inhibitory effects of apigenin involve modulation of IGF-axis signaling in prostate cancer.

Key words: insulin-like growth factor-I • insulin-like growth factor receptor-1 • insulin receptor substrate-1




This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
P. M. Yamada and K.-W. Lee
Perspectives in mammalian IGFBP-3 biology: local vs. systemic action
Am J Physiol Cell Physiol, May 1, 2009; 296(5): C954 - C976.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
X.-W. Hu, D. Meng, and J. Fang
Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase
Carcinogenesis, December 1, 2008; 29(12): 2369 - 2376.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
P. Kaur, S. Shukla, and S. Gupta
Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study
Carcinogenesis, November 1, 2008; 29(11): 2210 - 2217.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F.-M. Lin, L.-R. Chen, E.-H. Lin, F.-C. Ke, H.-Y. Chen, M.-J. Tsai, and P.-W. Hsiao
Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells
Carcinogenesis, December 1, 2007; 28(12): 2521 - 2529.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Shukla, G. T. MacLennan, C. A. Flask, P. Fu, A. Mishra, M. I. Resnick, and S. Gupta
Blockade of {beta}-Catenin Signaling by Plant Flavonoid Apigenin Suppresses Prostate Carcinogenesis in TRAMP Mice
Cancer Res., July 15, 2007; 67(14): 6925 - 6935.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Yin, J. Ni, M. Chen, M. A. DiMaggio, Y. Guo, and S. Yeh
The Therapeutic and Preventive Effect of RRR-{alpha}-Vitamin E Succinate on Prostate Cancer via Induction of Insulin-Like Growth Factor Binding Protein-3
Clin. Cancer Res., April 1, 2007; 13(7): 2271 - 2280.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
N. Khan, F. Afaq, and H. Mukhtar
Apoptosis by dietary factors: the suicide solution for delaying cancer growth
Carcinogenesis, February 1, 2007; 28(2): 233 - 239.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
R. P Singh and R. Agarwal
Mechanisms of action of novel agents for prostate cancer chemoprevention.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Shukla and S. Gupta
Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft.
Mol. Cancer Ther., April 1, 2006; 5(4): 843 - 852.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by The Federation of American Societies for Experimental Biology.